Aller au contenu principal Activer le contraste adaptéDésactiver le contraste adapté
Plus de 40 000 produits accessibles à 0€ de frais de courtage
Découvrir Boursomarkets
Fermer

Positive initial data from a Phase 1 trial with Transgene's oncolytic virus TG6002
information fournie par Boursorama CP08/09/2020 à 17:45

Intravenous administration of TG6002 is well tolerated and induces the production of a chemotherapy agent (5-FU) via its replication in tumor cells



Strasbourg, France, September 8, 2020, 5:45 pm CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces first positive data from the Phase 1 clinical trial evaluating the intravenous administration of TG6002 in patients with advanced gastrointestinal tumors.

The trial aims at confirming the good tolerability of ascending doses of intravenous TG6002 and at providing the first translational data from this novel route of administration.

.../...

Valeurs associées

Euronext Paris +2.52%

0 commentaire

Signaler le commentaire

Fermer

Mes listes

Cette liste ne contient aucune valeur.